You know what really stands out for me in the analyst report“Public and private comparables carry multi-billion-dollar valuations. StageZero’s proprietary Aristotle liquid biopsy diagnostic panel is expansive (10 types of cancer can be identified) and showed solid performance metrics in a large trial. We expect Aristotle to launch in the U.S., Canada and Europe by Q1/21 – and in the meantime StageZero is generating revenues from Covid testing services at its Virginia lab.”
Can it be any clearer that we are heading in a direction that will not only be viable, sustainable and profitable for the company but bring massive returns for the investors. Good luck to all !